Skip to main content
SpringerLink
Log in

Klassifikation maligner Lymphome

Aktueller Stand

Classification of malignant lymphomas

Current situation

  • Schwerpunkt: Maligne Lymphome
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die Weltgesundheitsorganisation (WHO) plant eine Aktualisierung der WHO-Klassifikation maligner Lymphome.

Ziel der Arbeit

Darstellung neuer diagnostisch und klinisch relevanter Erkenntnisse aus dem Bereich der malignen Lymphome.

Material und Methoden

Eine selektive Literaturrecherche (http://www.ncbi.nlm.nih.gov) wurde mit den praktischen Erfahrungen der Autoren aus der klinisch-pathologischen Diagnostik kombiniert.

Ergebnisse

Vermehrt wurden in den letzten Jahren frühe Läsionen maligner Lymphome beschrieben, deren Progressionspotenzial z. T. noch unklar ist. Neue Grenzziehungen ergeben sich v. a. im Bereich der T-Zell-Lymphome. Prognostische Subgruppen lassen sich jedoch auch in der heterogenen Gruppe der diffusen großzelligen B-Zell-Lymphome abgrenzen. Neu beschriebene genetische Veränderungen erleichtern die differenzialdiagnostische Abgrenzung morphologisch ähnlicher Erkrankungen und können einen wichtigen diagnostischen Baustein darstellen.

Schlussfolgerungen

Grundlagenwissenschaftliche Erkenntnisse der letzten Jahre finden mehr und mehr Anwendung in der Diagnose von Lymphomen. Die Aktualisierung der WHO-Klassifikation wird dieser Entwicklung Rechnung tragen.

Abstract

Background

The World Health Organization (WHO) is planning an update of the WHO classification of malignant lymphomas.

Objective

To present new findings concerning the diagnostics and subclassification of malignant lymphomas.

Material and methods

A selective literature search (http://www.ncbi.nlm.nih.gov) was carried out and combined with the practical experiences of the authors in clinicopathological diagnostics.

Results

In recent years an increasing number of early lesions of malignant lymphomas have been described but the potential malignancy of these lesions is at least for some entities still uncertain. Newly defined entities have been described within the group of T-cell lymphomas and prognostic subgroups have been identified in the heterogeneous group of diffuse large B-cell lymphomas. Detection of mutations facilitates the differential diagnostics of morphologically similar diseases and can be an important component of the diagnostics.

Conclusion

Recent scientific insights are being included more and more into the diagnostics of lymphomas. The update of the WHO classification is a consequence of these developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Adam P, Schiefer A, Prill S et al (2012) Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod Pathol 25(12):1629–1636. doi:10.1038/modpathol.2012.117

    Article  CAS  PubMed  Google Scholar 

  2. Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119(1):188–191. doi:10.1182/blood-2011-08-368209

    Article  CAS  PubMed  Google Scholar 

  3. Attygalle AD, Cabecadas J, Gaulard P et al (2014) Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology 64(2):171–199. doi:10.1111/his.12251

    Article  PubMed  Google Scholar 

  4. Aukema SM, Siebert R, Schuuring E et al (2011) Double-hit B-cell lymphomas. Blood 117(8):2319–2331. doi:10.1182/blood-2010-09-297879

    Article  CAS  PubMed  Google Scholar 

  5. Carvajal-Cuenca A, Sua LF, Silva NM et al (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2):270–278. doi:10.3324/haematol.2011.052621

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cong P, Raffeld M, Teruya-Feldstein J et al (2002) In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 99(9):3376–3382

    Article  CAS  PubMed  Google Scholar 

  7. Ganapathi KA, Pittaluga S, Odejide OO et al (2014) Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 99(9):1421–1432. doi:10.3324/haematol.2014.107938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Grever MR, Blachly JS, Andritsos LA (2014) Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev 28(5):197–203. doi:10.1016/j.blre.2014.06.003

    Article  CAS  PubMed  Google Scholar 

  9. Hamadeh F, MacNamara SP, Aguilera NS et al (2014) MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol 28(4):564–574. doi:10.1038/modpathol.2014.120

    Article  PubMed  Google Scholar 

  10. Henopp T, Quintanilla-Martínez L, Fend F et al (2011) Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology 59(1):139–142. doi:10.1111/j.1365-2559.2011.03897.x

    Article  PubMed  Google Scholar 

  11. Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263. doi:10.1182/blood-2012-06-435842

    Article  CAS  PubMed  Google Scholar 

  12. Jiménez C, Sebastián E, Chillón MC et al (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 27(8):1722–1728. doi:10.1038/leu.2013.62

    Article  PubMed  Google Scholar 

  13. Koskela HLM, Eldfors S, Ellonen P et al (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366(20):1905–1913. doi:10.1056/NEJMoa1114885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kraan W, van Keimpema M, Horlings HM et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 28(3):719–720. doi:10.1038/leu.2013.348

    Article  PubMed  Google Scholar 

  15. Landgren O (2013) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematol Am Soc Hematol Educ Program 2013:478–487. doi:10.1182/asheducation-2013.1.478

    Article  Google Scholar 

  16. Mamessier E, Song JY, Eberle FC et al (2014) Early lesions of follicular lymphoma: a genetic perspective. Haematologica 99(3):481–488. doi:10.3324/haematol.2013.094474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Oschlies I, Salaverria I, Mahn F et al (2010) Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma – Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 95(2):253–259. doi:10.3324/haematol.2009.013177

    Article  PubMed  PubMed Central  Google Scholar 

  18. Parrilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124(9):1473–1480. doi:10.1182/blood-2014-04-571091

    Article  PubMed  PubMed Central  Google Scholar 

  19. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L et al (2013) Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 27:402–411. doi:10.1038/modpathol.2013.156

    PubMed  Google Scholar 

  20. Poulain S, Boyle EM, Tricot S et al (2015) Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol 170(2):285–287. doi:10.1111/bjh.13293

    Article  CAS  PubMed  Google Scholar 

  21. Sakata-Yanagimoto M, Enami T, Yokoyama Y et al (2014) Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci 105(6):623–629. doi:10.1111/cas.12408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118(1):139–147. doi:10.1182/blood-2011-01-330795

    Article  CAS  PubMed  Google Scholar 

  23. Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454–462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, France

    Google Scholar 

  25. Teixeira LS, Wotherspoon A (2015) The relationship between overt and in-situ lymphoma: a retrospective study of follicular and mantle cell lymphoma cases. Histopathology : doi:10.1111/his.12753

    Google Scholar 

  26. Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315. doi:10.1056/NEJMoa1014209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Treon SP, Xu L, Yang G et al (2012) MYD88 L265P Somatic Mutation in Waldenström’s Macroglobulinemia. N Engl J Med 367(9):826–833. doi:10.1056/NEJMoa1200710

    Article  CAS  PubMed  Google Scholar 

  28. Varettoni M, Arcaini L, Zibellini S et al (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121(13):2522–2528. doi:10.1182/blood-2012-09-457101

    Article  CAS  PubMed  Google Scholar 

  29. Wada DA, Law ME, Hsi ED et al (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 24(4):596–605. doi:10.1038/modpathol.2010.225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Xi L, Arons E, Navarro W et al (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119(14):3330–3332. doi:10.1182/blood-2011-09-379339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus 14, 24113, Kiel, Deutschland

    K. Koch & W. Klapper

Authors
  1. K. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Klapper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Koch.

Ethics declarations

Interessenkonflikt

K. Koch und W. Klapper geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Redaktion

W. Hiddemann, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koch, K., Klapper, W. Klassifikation maligner Lymphome. Internist 57, 206–213 (2016). https://doi.org/10.1007/s00108-015-0006-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-015-0006-6

Schlüsselwörter

Keywords

Search

Navigation